It is unknown whether Linagliptin, a DPP-4 inhibitor, will have any positive effect on human EPC function with two prominent cardiovascular risk factors co-existing such as CKD and T2DM. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.